|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
Glance at last issue:
, Y* M/ L7 e1 E9 k' D
0 ^6 V- l. y! K) k"Unlike diagnostic tests that use small sets of biomarkers to examine cells, the molecular model approach uses all of the thousands of pieces of information in a microarray. This results in a diagnostic test with remarkable sensitivity and specificity."--Scripps Research molecular biologist Jeanne Loring.
7 h( X5 o& l) w2 n' O/ v' k8 l7 h; | Z4 G) g- k4 R1 _8 x! N* M
“Through Yap1, alpha-catenin tells epidermal stem cells to either proliferate or not proliferate, depending on the needs of the tissue.”--Fernando Camargo, PhD, a principal investigator in Stem Cell Program at Children’s Hospital Boston.8 h: a6 E* E- V, F
' R* @+ j/ I# Z1 i
"We think an investment in NeoStem is a good way to participate in the growing potential of stem cells, where a significant breakthrough could happen over the next five years. We expect the Chinese pharmaceutical business to grow at least 20% over the next decade."--Shiv Kapoor, biotech analyst at investment firm Morgan Joseph.
( B* m6 ^- K3 ^) x$ f- |0 `& I; l& Y$ r. `: B
“It’s amazingly cool that we can dial adult cells all the way back to embryonic-like stem cells, but there are a lot of issues that still need to be addressed before iPS cells can be used to treat patients. So we wondered if we just want to treat a brain disease, do we really have to start with a skin cell, which has nothing to do with the brain, and push it all the way back to the point that it has potential to become anything? In this study, we developed ICSP cells using a cell from the organ we’re already interested in – the nervous system, in this case – and pushed it back just enough so it continued to divide, giving us a quantity that we were able to apply efficiently, safely and effectively to treat stroke injury in a rodent model.”--Evan Y. Snyder, M.D., Ph.D., director of Sanford-Burnham’s Stem Cells and Regenerative Biology Program and corresponding author of the study.# V l" l) ^1 D5 u& s' ^! Q
4 r. N! N: s% k1 H! x"Typically, if you're going to see these structures fail, they can fail early or they can fail late. But if you have them with this long of a follow-up, then you know they're going to do well over time."--Dr. Anthony Atala of Wake Forest University in North Carolina.
( k* s7 _+ F4 j& [+ W4 d
1 U+ y& o' x- x% I( e9 g$ Z) [“The hope is that what these cells do in the very early stages of life can be repeated much later in life by producing new blood vessels that circumvent damaged ones altogether.”--John Laird, medical director of the UC Davis Vascular Center.# U3 C- G+ w4 z5 ?& D$ _% M, f
9 U0 g6 P# V9 k% N
"If we are not allowed to protect our inventions in Germany, we won't be able to compete in the international market for new disease therapies."--Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University of Bonn in Germany.- ^) @- J8 _: ^. N6 M5 w! P+ E
/ L, r; O3 z$ B2 z2 K+ m" B1 X6 m
“Most other gene therapy strategies for HIV are all about putting something into the cell that will stop the virus. What I liked about this is, it’s just taking off the door knob (used by HIV) and you don’t have to keep taking off the door knob. Once it’s gone, it’s gone.”--Paula Cannon, an associate professor of molecular microbiology and immunology at USC.
- r& G8 v. T, o4 g7 r% s6 C: [3 \ |9 f G( @/ n2 X6 n
“Then, a very small needle is introduced to puncture the retina at a certain point. A small hole is created. Then, a cannula is introduced and a bleb is created subretinally. Once that is done, then the cells are injected into that bleb.”--Edmund Mickunas, vice president of Advanced Cell Technology’s regulatory division., @3 G* @2 D) k! ]( q
: i: s% Z: [% x9 _" {1 _“What we’re hearing on these websites promoting these unproven treatments is that regulatory agencies like the Food and Drug Administration and the pharmaceutical industry don’t want you to get better. And this resonates with people who are, in many cases, seriously ill, and who are frustrated by the perceived lack of progress in established medicine...A plurality of anecdotes does not constitute evidence. Just because people swear up and down that something works doesn’t make it true.”--Douglas Sipp, the manager of scientific communications at RIKEN Center for Developmental Biology in Kobe, Japan.
- u3 M- f6 `& S: T1 i9 A) c# I' S b9 E) h% N9 D
“When we report something good about stem cells, it gets picked up in the media, or in a blog that patients read. It gives them more ammunition to say that the FDA is stupid for denying access to treatments that seem like they should work.”--Jeanne Loring, PhD, director of the Center for Regenerative Medicine at the Scripps Research Institute in La Jolla, Calif.
7 W4 t' E& n" k3 P& O, i2 Y X, z& {9 ^. ^* g8 y' O+ C
“Tens of thousands of patients are being mistreated. In some, the treatments will disqualify them from receiving therapies that we know are at least somewhat effective. Also, failures of these unproven treatments will undoubtedly affect the public and private support of legitimate stem cell science...We are learning what kinds of stem cells can regenerate which kinds of failing organs. But we always remember that our first goal is to do no harm. That’s why we begin our tests in animals before moving into early phase clinical trials in humans, and at every stage we verify the solidity and reproducibility of the science and that the investigators have no potential commercial or personal conflicts of interest that could influence the outcome of the trials. Any attempt to commercialize unproven treatments in the absence of independent or regulatory oversight endangers not only the lives of those who receive the treatments, but also the entire field of regenerative medicine.”--Irving Weissman, MD, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and immediate past president of the International Society for Stem Cell Research, or ISSCR.
1 Q" r# l1 b- |8 L7 M
0 h& A0 \& E$ O8 F* ]4 D$ X! I( E9 z1 t9 m
This issue:& x0 [# y7 M" q; v% B- I( y, O
4 L! @ }- A4 `9 O! Q
6 [* U" w% G$ ?% U1 r0 m3 U+ `
/ v& m0 W; \3 r( dVideo news:
4 a# r3 e! i4 G& b" x$ Q- l- \7 DResearch Trend of Regenerative Medicine, from BIT's 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010./ [$ D4 _$ K( l
http://mannovas.com/FeatureDetail/tabid/97/Default.aspx?fId=72
: u4 |3 Z. P3 o* w; Q# E. ] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 23
包包 + 40
查看全部评分
|
发表于 2011-3-17 20:43
